## 2 Results and Discussion
### Results
#### 2.1.4 Bioarth Scale Assessment  
Global Scores of all the variables assessed with the Bioarth scale for hip OA in both groups at baseline and its outcomes are summarized in Table 3. \begin{table}
\begin{tabular}{c c c c c c c c c c} \hline \hline \multirow{2}{*}{**Variable**} & \multirow{2}{*}{**Time**} & \multirow{2}{*}{**Group**} & \multirow{2}{*}{\(N\)**} & \multirow{2}{*}{**Mean**} & \multicolumn{2}{c}{**Std.**} & \multicolumn{2}{c}{**95\% Confidence Interval for Mean**} & \multicolumn{2}{c}{**\(p\)-Value between**} \\  & & & & & **Deviation** & **Lower Bound** & **Upper Bound** & & **Groups** \\ \hline \multirow{6}{*}{Owner VAS} & aMSCs & 34 & 28.6353 & 14.33904 & 23.6322 & 33.6384 & 6.57 & 53.94 & \multirow{6}{*}{0.001} \\  & baseline & PRGF & 36 & 42.9756 & 20.61379 & 36.0009 & 49.9503 & 9.21 & 72.37 & \multirow{6}{*}{0.001} \\  & & Total & 70 & 36.0103 & 19.13089 & 31.4487 & 40.5719 & 6.57 & 72.37 & \\ \cline{2-10}  & & aMSCs & 34 & 15.4312 & 11.03277 & 11.5817 & 19.2807 & 0.00 & 48.68 & \multirow{6}{*}{0.000} \\  & 1 month & PRGF & 36 & 27.5978 & 13.61288 & 22.9918 & 32.2037 & 5.92 & 59.21 & \multirow{6}{*}{0.000} \\  & & Total & 70 & 21.6883 & 13.77408 & 18.4040 & 24.9726 & 0.00 & 59.21 & \\ \cline{2-10}  & & aMSCs & 34 & 17.5500 & 15.87660 & 12.0104 & 23.0896 & 1.31 & 57.89 & \multirow{6}{*}{0.014} \\  & 3 months & PRGF & 36 & 27.4081 & 16.72219 & 21.7501 & 33.0660 & 4.60 & 72.37 & \multirow{6}{*}{0.014} \\  & & Total & 70 & 22.6199 & 16.94175 & 18.5802 & 26.6595 & 1.31 & 72.37 & \\ \cline{2-10}  & & aMSCs & 30 & 16.8620 & 13.55143 & 11.8018 & 21.9222 & 2.63 & 51.31 & \multirow{6}{*}{0.046} \\  & 6 months & PRGF & 34 & 24.6088 & 16.43983 & 18.8727 & 30.3450 & 0.00 & 56.58 & \multirow{6}{*}{0.046} \\  & & Total & 64 & 20.9775 & 15.53332 & 17.0974 & 24.8576 & 0.00 & 56.58 & \\ \hline \multirow{6}{*}{baseline} & aMSCs & 34 & 23.8200 & 10.77498 & 20.0604 & 27.5796 & 6.57 & 50.66 & \multirow{6}{*}{0.000} \\  & & PRGF & 36 & 32.9692 & 9.88435 & 29.6248 & 36.3136 & 10.60 & 48.68 & \multirow{6}{*}{0.000} \\  & & Total & 70 & 28.5253 & 11.23820 & 25.8456 & 31.2049 & 6.57 & 50.66 & \\ \cline{2-10}  & & aMSCs & 34 & 14.0894 & 6.38365 & 11.8621 & 16.3168 & 6.57 & 32.89 & \multirow{6}{*}{0.000} \\  & 1 month & PRGF & 36 & 24.8964 & 7.74936 & 22.2744 & 27.5184 & 8.00 & 42.76 & \multirow{6}{*}{0.000} \\  & & Total & 70 & 19.6473 & 8.91895 & 17.5206 & 21.7739 & 6.57 & 42.76 & \\ \cline{2-10}  & & aMSCs & 34 & 10.8635 & 5.89049 & 8.8082 & 12.9188 & 3.95 & 26.31 & \multirow{6}{*}{0.000} \\  & 3 months & PRGF & 36 & 22.0383 & 7.50788 & 19.4980 & 24.5786 & 6.00 & 40.79 & \multirow{6}{*}{0.000} \\  & & Total & 70 & 16.6106 & 8.76544 & 14.5205 & 18.7006 & 3.95 & 40.79 & \\ \cline{2-10}  & & aMSCs & 32 & 9.5306 & 5.77949 & 7.4469 & 11.6144 & 3.95 & 29.60 & \multirow{6}{*}{0.000} \\  & 6 months & PRGF & 34 & 24.8297 & 8.75538 & 21.7748 & 27.8846 & 6.00 & 50.00 & \multirow{6}{*}{0.000} \\  & & Total & 66 & 17.4120 & 10.68689 & 14.7848 & 20.0391 & 3.95 & 50.00 & \\ \hline \hline \end{tabular}
\end{table} 
Table 2: The mean VAS (\(\pm\)SD) assessed by the dog owners and by the investigator at each time point. For statistical purposes, the Kruskal Wallis Test was applied (Spss Statistics for MAC, version 20, IBM, Madrid, Spain). Differences between groups are shown as \(p\)-value between groups. \(p<0.05\) is considered statistically significant.